Rallybio (RLYB) Retained Earnings (2020 - 2026)
Rallybio (RLYB) posted Retained Earnings of -$310.3 million for Q1 2026, down 1723855.56% sequentially from $18000.0 in Q4 2025, and down 187.04% YoY from $356.5 million in Q1 2025.
Rallybio (RLYB) Retained Earnings (2020 - 2026) Analysis & Trends
Rallybio has reported Retained Earnings for 7 years, with the latest figure at -$310.3 million in Q1 2026.
- Quarterly Retained Earnings fell 187.04% year-over-year to -$310.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$310.3 million (down 187.04% YoY) and the FY2025 annual result came in at $18000.0, down 99.99% from the prior year.
- Retained Earnings declined to -$310.3 million in Q1 2026 per RLYB's latest filing, from $18000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $358.1 million in Q2 2025 and troughed at -$310.3 million in Q1 2026.
- A 5-year average of $73.6 million and a median of $15000.0 in 2023 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 2363913.33% in 2024, down 135465.38% in 2024.
- Over 5 years, Retained Earnings stood at -$160.7 million in 2022, then surged by 100.01% to $15000.0 in 2023, then jumped by 2363913.33% to $354.6 million in 2024, then tumbled by 99.99% to $18000.0 in 2025, then sank by 1723855.56% to -$310.3 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$310.3 million, $18000.0, and -$296.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 361.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 361.10 Mn |
| Mar 31, 2026 | -310.28 Mn |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | -296.15 Mn |
| Jun 30, 2025 | 358.11 Mn |
| Mar 31, 2025 | 356.48 Mn |
| Dec 31, 2024 | 354.60 Mn |
| Sep 30, 2024 | -281.98 Mn |
| Jun 30, 2024 | 350.59 Mn |
| Mar 31, 2024 | -71,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Sep 30, 2023 | -208,000.00 |
| Jun 30, 2023 | -272,000.00 |
| Mar 31, 2023 | 333.25 Mn |
| Dec 31, 2022 | -160.68 Mn |
| Sep 30, 2022 | 276.85 Mn |
| Jun 30, 2022 | -371,000.00 |
| Mar 31, 2022 | 271.68 Mn |
| Dec 31, 2021 | -94.03 Mn |
| Sep 30, 2021 | -81.61 Mn |